|
DGAP-News: Carl Zeiss Meditec AG
/ Key word(s): 9 Month figures
JENA, 5 August 2020 Carl Zeiss Meditec generated revenue of €967.9m in the first nine months of fiscal year 2019/20 (prior year: €1,027.6m), a decline of -5.8% (adjusted for currency effects: -6.9%) compared with the same period of the prior year. Earnings before interest and taxes (EBIT) decreased to €111.9m (prior year: €184.2m). The EBIT margin was 11.6% (prior year: 17.9%). "The effects of the COVID-19 pandemic impacted us significantly, particularly in the third quarter of fiscal year 2019/20. Although there has already been a slight recovery in some parts of APAC[1], the measures to contain the COVID-19 pandemic in Europe and North America had a marked effect on our customers and thus demand for our products," said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. Both strategic business units report declines in revenue Revenue in the Ophthalmic Devices strategic business unit (SBU) decreased by -7.0% in the first nine months of fiscal year 2019/20 (adjusted for currency effects: -8.0%), to €709.1m (prior year: €762.7m). Stable performance in APAC region - significant declines in EMEA[2] and Americas Revenue in the EMEA region decreased by -12.8% (adjusted for currency effects: -12.7%), to €268.8m (prior year: €308.2m). Declines were recorded particularly in the markets worst affected by the COVID-19 pandemic in Western Europe, the UK, Turkey and the Middle East region. In Germany, a recovery was well underway towards the end of the reporting period. The Americas region recorded a revenue decline of -6.9% (adjusted for currency effects: -9.0%), to €272.3m (prior year: €292.5m). In the third quarter, revenue decreased significantly in the USA and Brazil in particular, after both had achieved growth at the start of the fiscal year. With revenue of €426.8m, the APAC region almost reached the prior year's figure of €426.9m (adjusted for currency effects: -1.1%). That performance was bolstered by a robust recovery in China and South Korea in the third quarter, after in particular temporary closures of clinics and postponements of elective surgery had previously led to significant revenue losses in the months of February and March. The markets of Japan, India and Southeast Asia, on the other hand, showed a clear decline in the third quarter. Operating result below prior year The operating result (earnings before interest and taxes: EBIT) decreased in the first nine months of fiscal year 2019/20, to €111.9m (prior year: €184.2m). The EBIT margin declined to 11.6% (prior year: 17.9%). Adjusted for special items, this amounted to 12.1% (prior year: 18.2%). Earnings per share fell to €0.77 (prior year: €1.22). "As already announced in July, we are projecting revenue of around €1.3bn for fiscal year 2019/20. This is based on the assumption that the markets will continue to recover and that no additional measures to contain the COVID-19 pandemic will be necessary," added Dr. Ludwin Monz. "Our entire focus remains on protecting our employees, continuity of supply for our customers, and continuing with our strategic investments, so that we can return to sustainable growth as soon as possible."
Revenue by strategic business unit
Revenue by region
Contact for investors and press Sebastian Frericks
05.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena, Germany | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | investors.meditec@zeiss.com |
| Internet: | www.zeiss.de/meditec-ag/ir |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1110179 |
| End of News | DGAP News Service |
|
|
1110179 05.08.2020
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
